McMagyar, that is a good point about the FDA as I've wondered if it is influencing the release of the data in that the P 2/3 will be issued in conjunction with that data release. It might be its questions need to be resolved before any release as its decision to proceed is contingent on agreement with Anavex's data.
Additionally, if the FDA does have many questions, then Dr. MaxFarlane's sabbatical might be delaying the analysis and the responses to those questions.
News 
Market Data 
Discover 
